Viewing Study NCT07252232

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2026-01-05 @ 6:10 PM
Study NCT ID: NCT07252232
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2025-11-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor: Revolution Medicines, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Cancer View
None PDAC View
None PDAC - Pancreatic Ductal Adenocarcinoma View
None Resectable Pancreatic Ductal Adenocarcinoma (PDAC) View
None Resected Pancreatic Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Pancreatic Cancer View
None PDAC View
None Pancreatic Ductal Adenocarcinoma View
None RAS View
None KRAS View
None NRAS View
None HRAS View
None RAS Wild-Type View
None RASolute View
None Resectable Pancreatic Ductal Adenocarcinoma View
None Resectable PDAC View
None Resected Pancreatic Adenocarcinoma View
None RAS Mutation View